Jyong Biotech Targets $22B BPH Market with Global Licensing Push
Event summary
- Jyong Biotech reaffirms focus on global licensing partnerships for its BPH treatment Botreso® (API-1).
- Global BPH market projected to grow from $13B in 2025 to $22.6B by 2035.
- Botreso® completed Phase III trials involving over 200 urologists in Taiwan and the US.
The big picture
Jyong Biotech is capitalizing on the growing BPH market driven by global population aging. The company's botanical drug approach aims to address high discontinuation rates of current treatments, positioning it as a potential disruptor in the $22B market. Success hinges on securing strategic licensing partnerships and navigating regulatory approvals.
What we're watching
- Regulatory Approval
- Whether Botreso® can secure FDA approval after Phase III trials.
- Partnership Execution
- The pace at which Jyong Biotech finalizes licensing deals with international pharma companies.
- Market Penetration
- How Jyong Biotech positions Botreso® against existing BPH treatments with high discontinuation rates.
Related topics